Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$2.43 -1.2%	$2.74	$2.06 ▼ $24.93	$7.13M	-0.32	98,048 shs	30,818 shs
CASI CASI Pharmaceuticals	$2.44 +9.4%	$1.62	$1.09 ▼ $7.67	$27.43M	0.63	3.73 million shs	68,635 shs
CVKD Cadrenal Therapeutics	$13.29 -4.6%	$11.80	$6.89 ▼ $22.90	$28.51M	0.93	33,896 shs	35,865 shs
TENX Tenax Therapeutics	$5.93 +0.2%	$5.95	$3.25 ▼ $7.89	$27.01M	1.46	23,162 shs	4,012 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+0.82%	+8.85%	-11.19%	-54.78%	-89.24%
CASI CASI Pharmaceuticals	-2.62%	-2.19%	+37.65%	+19.00%	-65.75%
CVKD Cadrenal Therapeutics	+1.31%	+8.57%	+20.29%	+4.27%	+76.33%
TENX Tenax Therapeutics	+0.34%	-1.00%	-3.74%	-3.74%	+48.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALZN Alzamend Neuro	2.8662 of 5 stars	3.5	2.0	0.0	2.3	3.3	0.6
CASI CASI Pharmaceuticals	4.0722 of 5 stars	3.5	3.0	4.3	2.7	1.7	0.0
CVKD Cadrenal Therapeutics	3.0734 of 5 stars	3.5	3.0	0.0	3.8	1.7	0.6
TENX Tenax Therapeutics	1.4649 of 5 stars	3.6	1.0	0.0	1.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	3.00	Buy	$45.00	1,751.85% Upside
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	63.93% Upside
CVKD Cadrenal Therapeutics	3.00	Buy	$32.00	140.78% Upside
TENX Tenax Therapeutics	3.25	Buy	$17.00	186.68% Upside

Current Analyst Ratings Breakdown

Latest ALZN, TENX, CVKD, and CASI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/21/2025	ALZN Alzamend Neuro	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$180.00 ➝ $45.00
8/14/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$4.95 per share	N/A
CASI CASI Pharmaceuticals	$28.54M	1.05	N/A	N/A	$0.12 per share	20.33
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$2.10 per share	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$22.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$4.51M	N/A	0.00	N/A	N/A	N/A	-181.34%	-116.84%	9/10/2025 (Estimated)
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/29/2025 (Estimated)
CVKD Cadrenal Therapeutics	-$10.65M	-$8.88	0.00	N/A	N/A	N/A	-265.37%	-196.38%	11/6/2025 (Estimated)
TENX Tenax Therapeutics	-$17.60M	-$0.92	N/A	N/A	N/A	N/A	-31.34%	-30.39%	11/12/2025 (Estimated)

Latest ALZN, TENX, CVKD, and CASI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2025	N/A	ALZN Alzamend Neuro	-$3.69	N/A	N/A	N/A	N/A	N/A
8/29/2025	N/A	CASI CASI Pharmaceuticals	-$0.47	N/A	N/A	N/A	$6.28 million	N/A
8/13/2025	Q2 2025	TENX Tenax Therapeutics	-$0.50	-$0.27	+$0.23	-$0.27	N/A	N/A
8/11/2025	Q2 2025	CVKD Cadrenal Therapeutics	-$1.60	-$1.87	-$0.27	-$1.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	6.58	6.58
CASI CASI Pharmaceuticals	N/A	0.81	0.68
CVKD Cadrenal Therapeutics	N/A	3.55	3.55
TENX Tenax Therapeutics	N/A	41.89	41.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
CASI CASI Pharmaceuticals	22.23%
CVKD Cadrenal Therapeutics	7.92%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	30.21%
CASI CASI Pharmaceuticals	21.24%
CVKD Cadrenal Therapeutics	26.09%
TENX Tenax Therapeutics	3.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	2.90 million	2.02 million	No Data
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
CVKD Cadrenal Therapeutics	4	2.05 million	1.51 million	Not Optionable
TENX Tenax Therapeutics	9	4.56 million	4.42 million	Not Optionable

ALZN, TENX, CVKD, and CASI Headlines

Recent News About These Companies

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

August 28 at 7:00 AM | globenewswire.com

Leerink Partnrs Has Negative Forecast for TENX Q3 Earnings

August 19, 2025 | americanbankingnews.com

William Blair Brokers Decrease Earnings Estimates for TENX

August 19, 2025 | americanbankingnews.com

Q3 EPS Estimate for Tenax Therapeutics Reduced by Analyst

August 18, 2025 | americanbankingnews.com

Equities Analysts Set Expectations for TENX FY2028 Earnings

August 17, 2025 | americanbankingnews.com

Tenax Posts Wider Loss in Fiscal Q2

August 14, 2025 | aol.comA

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

August 14, 2025 | msn.com

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

TENX Tenax Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Tenax Therapeutics Inc.

May 9, 2025 | barrons.com

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

April 16, 2025 | seekingalpha.com

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

April 16, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics (TENX) Gets a Buy from William Blair

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics: Q4 Earnings Snapshot

March 25, 2025 | timesunion.comT

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

Tenax Therapeutics Inc TENX

March 14, 2025 | morningstar.comM

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

March 6, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, TENX, CVKD, and CASI Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$2.43 -0.03 (-1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$2.44 +0.01 (+0.62%)

As of 07:50 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

CASI Pharmaceuticals NASDAQ:CASI

$2.44 +0.21 (+9.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.06 (+2.25%)

As of 07:38 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Cadrenal Therapeutics NASDAQ:CVKD

$13.29 -0.64 (-4.59%)

Closing price 04:00 PM Eastern

Extended Trading

$14.14 +0.85 (+6.43%)

As of 05:11 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Tenax Therapeutics NASDAQ:TENX

$5.93 +0.01 (+0.17%)

Closing price 03:58 PM Eastern

Extended Trading

$5.93 0.00 (0.00%)

As of 04:52 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time